204 related articles for article (PubMed ID: 37681411)
1. Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models.
Matsukawa T; Yagi T; Uchida T; Sakai M; Mitsushima M; Naganuma T; Yano H; Inaba Y; Inoue H; Yanagida K; Uematsu M; Nakao K; Nakao H; Aiba A; Nagashima Y; Kubota T; Kubota N; Izumida Y; Yahagi N; Unoki-Kubota H; Kaburagi Y; Asahara SI; Kido Y; Shindou H; Itoh M; Ogawa Y; Minami S; Terauchi Y; Tobe K; Ueki K; Kasuga M; Matsumoto M
JCI Insight; 2023 Sep; 8(17):. PubMed ID: 37681411
[TBL] [Abstract][Full Text] [Related]
2. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes.
Liu Y; Lin H; Jiang L; Shang Q; Yin L; Lin JD; Wu WS; Rui L
J Clin Invest; 2020 Jun; 130(6):2992-3004. PubMed ID: 32365055
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
Zhang M; Tang Y; Tang E; Lu W
Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
[TBL] [Abstract][Full Text] [Related]
5. Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
Hu Y; He W; Huang Y; Xiang H; Guo J; Che Y; Cheng X; Hu F; Hu M; Ma T; Yu J; Tian H; Tian S; Ji YX; Zhang P; She ZG; Zhang XJ; Huang Z; Yang J; Li H
Hepatology; 2021 Nov; 74(5):2508-2525. PubMed ID: 34231239
[TBL] [Abstract][Full Text] [Related]
6. Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor.
Wang Z; Miu KK; Zhang X; Wan AT; Lu G; Cheung HH; Lee HM; Kong AP; Chan JC; Chan WY
JHEP Rep; 2020 Dec; 2(6):100179. PubMed ID: 33134908
[TBL] [Abstract][Full Text] [Related]
7. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
8. The Different Mechanisms of Lipid Accumulation in Hepatocytes Induced by Oleic Acid/Palmitic Acid and High-Fat Diet.
Zhang M; Bai X; Du Q; Xu J; Wang D; Chen L; Dong K; Chen Z; Yang J
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764494
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
[TBL] [Abstract][Full Text] [Related]
10. Expression of fatty acid synthase in nonalcoholic fatty liver disease.
Dorn C; Riener MO; Kirovski G; Saugspier M; Steib K; Weiss TS; Gäbele E; Kristiansen G; Hartmann A; Hellerbrand C
Int J Clin Exp Pathol; 2010 Mar; 3(5):505-14. PubMed ID: 20606731
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Hepatocellular Fatty Acid Uptake in Mouse Models of Fatty Liver Disease with and without Functional Leptin Signaling: Roles of NfKB and SREBP-1C and the Effects of Spexin.
Ge JF; Walewski JL; Anglade D; Berk PD
Semin Liver Dis; 2016 Sep; 36(4):360-372. PubMed ID: 27997977
[TBL] [Abstract][Full Text] [Related]
12. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
[TBL] [Abstract][Full Text] [Related]
14. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
[TBL] [Abstract][Full Text] [Related]
16. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver.
Hörbelt T; Knebel B; Fahlbusch P; Barbosa D; de Wiza DH; Van de Velde F; Van Nieuwenhove Y; Lapauw B; Thoresen GH; Al-Hasani H; Müller-Wieland D; Ouwens DM; Kotzka J
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2671-2684. PubMed ID: 31336149
[TBL] [Abstract][Full Text] [Related]
17. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
18. Histone modifications in fatty acid synthase modulated by carbohydrate responsive element binding protein are associated with non‑alcoholic fatty liver disease.
Cai C; Yu H; Huang G; Du X; Yu X; Zhou Y; Shen W
Int J Mol Med; 2018 Sep; 42(3):1215-1228. PubMed ID: 29786745
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors.
Angeles TS; Hudkins RL
Expert Opin Drug Discov; 2016 Dec; 11(12):1187-1199. PubMed ID: 27701891
[TBL] [Abstract][Full Text] [Related]
20. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
